Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with ...

A new research paper was published in Volume 12 of Oncoscience on October 14, 2025, titled "Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA ...

Opportunistic salpingectomy (OS) is feasible but not performed in almost a quarter of patients later diagnosed with high-grade serous carcinoma (HGSC), and about 40% of patients with a first-degree ...

Scientists at The University of Texas at El Paso have found a promising new target in the fight against high-grade serous carcinoma, an aggressive form of ovarian cancer. Less than 50 percent of women ...

Figure 1: Hemocytometer dead cells count. Here is the bar graph showing the hemocytometer based dead cell counts for each treatment group across day 1, day 2 and day 4 (24 hours post treatment). The ...

ANN ARBOR, Michigan — A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments. High-grade serous carcinoma, ...

Characterization of copy number variations (CNV) patterns and pseudotime trajectories in high-grade serous ovarian cancer (HGSOC). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...

Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, ...